STAT3 and ovarian carcinoma: Prior studies on similar analogs, including compounds #7 and #11, showed clear activity against AR/AR-SVs in PCa, Wnt-ß-catenin, mTORC1, and STAT3 in ovarian cancer and NF-κB in breast cancer [23,29,30,32].